Table 2.

Dose, dose-function, and difference between dose-function and dose metrics provided for both stage I and stage III lung cancer patients.

	Stage I	Stage III
Dose-volume metrics
MLD (Gy)	4.6	20.7
V5 (%)	24.3	68.4
V10 (%)	13.5	51.7
V20 (%)	6.7	34.0
V30 (%)	3.6	27.5
Dose-function metrics
fMLD (Gy)	5.4	19.6
fV5 (%)	25.8	66.9
fV10 (%)	14.7	49.1
fV20 (%)	7.3	31.0
fV30 (%)	3.7	24.7
meanF80 (Gy)	4.6	19.8
differences between dose and dose-function metrics: mean (min - max)
diff MLD (%)	0.8 (−4.3 to 4.1)	−1.1 (−7.8 to 5.0)
diff V5 (%)	1.5 (−13.5 to 15.8)	−1.4 (−11.8 to 13.3)
dff V10 (%)	1.2 (−9.1 to 11.0)	−2.7 (−15.2 to 11.8)
diff V20 (%)	0.5 (−11.4 to 9.2)	−3.0 (−15.1 to 10.2)
diff V30 (%)	0.1 (−8.8 to 6.1)	−2.8 (−14.1 to 10.6)

Abbreviations: MLD=Mean lung dose, V5=percentage of lung receiving 5 Gy or less, fMLD=functionally weighted mean, fV5=percentage of lung receiving 5 Gy or less using the dose-function histogram formulation), diff = corresponding dose metric subtracted from the dose-volume metric